In an adult patient with snoring, witnessed apneas, excessive daytime sleepiness or fatigue, how can I distinguish obstructive sleep apnea (OSA) from obesity hypoventilation syndrome (OHS) and what are the initial treatment approaches for each?

Distinguishing OSA from OHS and Initial Treatment

The key distinction is that OHS requires documented daytime hypercapnia (PaCO₂ ≥45 mmHg) in an obese patient (BMI ≥30 kg/m²), while OSA does not involve daytime hypercapnia. Both conditions share similar presenting symptoms (snoring, witnessed apneas, excessive daytime sleepiness), making biochemical testing essential for differentiation 1.

Diagnostic Approach to Distinguish OSA from OHS

Clinical Clues Suggesting OHS Rather Than Pure OSA

When evaluating an obese patient with sleep-disordered breathing symptoms, suspect OHS if:

• BMI is markedly elevated (typically >40 kg/m²) 2
• Daytime hypoxemia is present (SaO₂ ≤95% has 64.4% sensitivity and 73.9% specificity for OHS) 3
• More severe daytime sleepiness (higher Epworth Sleepiness Scale scores) 3, 4
• Comorbid hypertension (present in 68% of OHS vs 53% of pure OSA) 3
• Restrictive pulmonary function with reduced FVC% and FEV1% 3

Biochemical Screening Strategy

Use serum bicarbonate as the initial screening test: A bicarbonate level <27 mmol/L effectively excludes OHS when clinical suspicion is not very high (<20%), with 88.1% sensitivity and 73.1% specificity 1, 3. However, if clinical suspicion is high or bicarbonate ≥27 mmol/L, proceed directly to arterial blood gas measurement to confirm or exclude daytime hypercapnia 1.

This algorithmic approach is critical because:

• OHS patients have significantly elevated bicarbonate levels (compensatory metabolic alkalosis) 3
• Arterial blood gases remain the gold standard, showing PaCO₂ ≥45 mmHg in OHS 1
• Other causes of hypoventilation must be excluded 1, 5

Polysomnography Findings

While both conditions require sleep study confirmation, OHS patients demonstrate:

• More severe nocturnal hypoxemia (lower mean and nadir SpO₂, increased time with SpO₂ <90%) 3, 4
• Higher apnea-hypopnea index (mean difference of 8.36 events/hour higher than pure OSA) 2
• More sleep fragmentation (higher arousal index) 4

Important caveat: Approximately 20% of OHS patients may not have significant OSA, presenting with isolated nocturnal hypoventilation 6, 7.

Initial Treatment Approaches

For Pure OSA (Without Daytime Hypercapnia)

Initiate CPAP or APAP as first-line therapy 8. The treatment algorithm is:

1. Start with either APAP at home or in-laboratory PAP titration (both equally effective for patients without significant comorbidities) 8
2. Use CPAP or APAP for ongoing treatment (CPAP or APAP preferred over BPAP for routine OSA) 8
3. Provide educational interventions at PAP initiation (strong recommendation to improve adherence) 8
4. Consider behavioral/troubleshooting interventions and telemonitoring during the initial period to optimize adherence 8

For OHS (With Daytime Hypercapnia)

The treatment approach differs based on clinical presentation:

Stable Ambulatory OHS Patients

If severe OSA coexists (which occurs in ~80% of OHS cases), start with CPAP rather than noninvasive ventilation (NIV) as first-line therapy 1. This conditional recommendation is based on:

• CPAP is simpler, less expensive, and better tolerated initially
• Many OHS patients with severe OSA respond adequately to CPAP alone
• NIV can be reserved for those who remain hypercapnic despite adequate CPAP adherence

If OSA is absent or minimal (~20% of OHS cases), initiate NIV (bilevel PAP) directly 6, 7.

Hospitalized OHS Patients with Acute-on-Chronic Respiratory Failure

Discharge patients on NIV (bilevel PAP) rather than CPAP until outpatient diagnostic procedures and PAP titration can be completed in a sleep laboratory, ideally within 2-3 months 1. This approach reduces morbidity and prevents readmission in this high-risk population.

Weight Loss as Definitive Therapy

Recommend weight-loss interventions targeting sustained loss of 25-30% of body weight to achieve resolution of OHS 1. Bariatric surgery is more likely to achieve this magnitude of weight loss compared to lifestyle interventions alone 1. This addresses the underlying pathophysiology and can lead to complete resolution.

Critical Pitfalls to Avoid

• Do not assume all obese patients with sleep-disordered breathing have pure OSA—failure to check daytime blood gases or bicarbonate leads to missed OHS diagnoses 9, 5
• Do not rely solely on symptoms to distinguish the conditions—they overlap substantially and require biochemical confirmation 3
• Do not discharge hospitalized patients with suspected OHS on CPAP alone—use NIV until proper outpatient evaluation 1
• Do not overlook OHS in patients with bicarbonate ≥27 mmol/L—this warrants arterial blood gas measurement 1

The evidence quality for OHS management is admittedly low (very low quality per GRADE criteria), but the conditional recommendations from the 2019 ATS guideline represent the best available guidance and emphasize early recognition to reduce the substantial morbidity and mortality associated with untreated OHS 1, 9.